ItAlian, Multicenter, Observational, Prospective sTudy to Evaluate the acHievement of Clinical rEmission and immuNomodulation in Severe Eosinophilic Asthma Patients Treated With Benralizumab - the ATHENA Study
Status: Recruiting
Location: See all (28) locations...
Intervention Type: Biological
Study Type: Observational
SUMMARY
This is an observational, multicenter, prospective study on patients with severe eosinophilic asthma treated with benralizumab aimed at evaluating the achievement of partial and complete clinical remission.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Adults (≥ 18 years old) diagnosed with severe uncontrolled eosinophilic asthma.
• Benralizumab has been prescribed according to the approved label and local reimbursement criteria
• Provision of signed Informed Consent Form (ICF) prior to any study-related activities
• Benralizumab has been initiated within 7 days prior to study enrollment or is planned to be initiated within 7 days after enrollment (in the latter case, provided that the decision to prescribe benralizumab is made prior to the decision to enroll the patient in the study).
Locations
Other Locations
Italy
Research Site
RECRUITING
Bari
Research Site
NOT_YET_RECRUITING
Bergamo
Research Site
RECRUITING
Bologna
Research Site
NOT_YET_RECRUITING
Bologna
Research Site
NOT_YET_RECRUITING
Brescia
Research Site
NOT_YET_RECRUITING
Catania
Research Site
RECRUITING
Catanzaro
Research Site
NOT_YET_RECRUITING
Florence
Research Site
NOT_YET_RECRUITING
Foggia
Research Site
NOT_YET_RECRUITING
Messina
Research Site
RECRUITING
Milan
Research Site
RECRUITING
Modena
Research Site
RECRUITING
Naples
Research Site
NOT_YET_RECRUITING
Naples
Research Site
NOT_YET_RECRUITING
Padova
Research Site
NOT_YET_RECRUITING
Padova
Research Site
RECRUITING
Palermo
Research Site
NOT_YET_RECRUITING
Pavia
Research Site
RECRUITING
Roma
Research Site
NOT_YET_RECRUITING
Roma
Research Site
NOT_YET_RECRUITING
Salerno
Research Site
NOT_YET_RECRUITING
Sassari
Research Site
NOT_YET_RECRUITING
Siena
Research Site
RECRUITING
Teramo
Research Site
RECRUITING
Torino
Research Site
RECRUITING
Treviso
Research Site
RECRUITING
Varese
Research Site
NOT_YET_RECRUITING
Verona
Contact Information
Primary
AstraZeneca Clinical Study Information Center
information.center@astrazeneca.com
1-877-240-9479
Time Frame
Start Date: 2025-12-20
Estimated Completion Date: 2028-12-31
Participants
Target number of participants: 335
Related Therapeutic Areas
Sponsors
Leads: AstraZeneca